BeyondSpring Inc. Aktie

1,75 $

2,23 %

Nasdaq , 30. Juni, 16:00 Uhr EDT. Geschlossen.

ISIN

KYG108301006

Symbol

BYSI

Berichte

Quartal | Jahr

Index

NASDAQ Composite

Sektor

Pharma, Biotechnologie und Life Sciences

Industrie

Biotechnologie

Mit

tracken

Übersicht Analysten Charts Ownership News Strategien

BeyondSpring Inc. Aktienkurs

1,75 $

-8,69 83,24 % 5 J.

Nasdaq, Schlusskurs Di, 30.06.2026

-0,04 2,23 %

ISIN

KYG108301006

Symbol

BYSI

Berichte

Quartal | Jahr

Index

NASDAQ Composite

Sektor

Pharma, Biotechnologie und Life Sciences

Industrie

Biotechnologie

Als kostenloser aktien.guide Basis-Nutzer kannst Du die Scores zu allen 7.930 weltweiten Aktien einsehen.

Jetzt kostenlos registrieren

Kennzahlen

Basis

Marktkapitalisierung

73,6 Mio. $

Enterprise Value

65,7 Mio. $

Nettoverschuldung

positiv

Cash

7,9 Mio. $

Anzahl Aktien

41,1 Mio.

Bewertung (TTM | erwartet)

KGV

negativ

KUV

- | -

EV/Sales

- | -

EV/FCF

negativ

KBV

negativ

Finanzielle Stabilität

Eigenkapitalquote

-124,0 %

Eigenkapitalrendite

3,1 %

ROCE

-141,8 %

ROIC

-2.326,3 %

Verschuldungsgrad

0,0

Finanzen (TTM | erwartet)

Umsatz

0,0 $ | -

EBITDA

-8,5 Mio. $

EBIT

-8,6 Mio. $

Nettogewinn

-7,6 Mio. $

Free Cashflow

-18,9 Mio. $

Wachstum (TTM | erwartet)

Umsatz

- | -

EBITDA

4,5 %

EBIT

8,0 %

Nettogewinn

-123,4 %

Free Cashflow

9,9 %

Marge

Brutto

EBITDA

EBIT

Netto

Free Cashflow

Weitere

EPS

-0,2 $

FCF je Aktie

-0,5 $

Short Interest

6,5 %

Mitarbeiter

Umsatz je MA

0,0 $

BeyondSpring Inc. Aktie Analyse

Scores kostenlos freischalten

??

7 Analysten haben eine BeyondSpring Inc. Prognose abgegeben:

6x Kaufen

86 %

Mehr Details zu Analystenschätzungen inkl. Kursziele

7 Analysten haben eine BeyondSpring Inc. Prognose abgegeben:

Kaufen

86 %

Halten

14 %

Analystenschätzungen inkl. Kursziele

Beta BeyondSpring Inc. Events

Vergangene Events

SEP

Shareholder/Analyst Call - BeyondSpring Inc.

vor 10 Monaten

1. Management Discussion

Unknown Attendee

Good morning, and welcome to the 2025 Annual Meeting of Shareholders of BeyondSpring Inc.

Lan Huang executive

Good morning. I'm Lan Huang, Chair of Board of Directors and Chief Executive Officer of BeyondSpring Inc. It's my great pleasure to preside over our company's 2025 Annual Meeting. This meeting is officially called to order. I'd like to thank Richard [ Ho Young ] from our independent auditor, CBIZ, who is in attendance at today's meeting.

A notice of the meeting was sent to all shareholders of record as of the close of business day on August 6, 2025. Only shareholders of record on that date are entitled to vote.

I'm informed by our Inspector of Election that the holders of more than a majority of the total number of outstanding shares of common share entitled to vote are present, either virtually or by proxy. So a quorum is present.

The polls are open for voting through the web portal. Shareholders who would like to vote, may do so now and follow the instructions there. The polls will be closed following the discussion of today's business items.

The first and only item is the ratification of the appointment of CBIZ as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Our Board recommended that our shareholders vote for the ratification of authority.

If a shareholder would like to make a comment regarding the proposal, please submit your comments through the web portal. If there is no further discussion regarding the proposals, we will now proceed to vote.

Any shareholders still wishing them to vote should do so right now. If you have already sent in your proxy or voted via telephone or Internet and do not want to change your vote, you do not need to take any further action. I will pause for a moment for any final voting.

[Voting]

Lan Huang executive

Now that everyone has had opportunity to vote, I now declare the polls closed. I'm pleased to report that a majority of votes cast have been voted in favor of the ratification of the appointment of CBIZ as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

We greatly value shareholder input. Any questions submitted will be carefully reviewed and addressed after the meeting through our transfer agent. Complete voting results will be filed with the Form 8-K that will be posted on the sec.gov website, following the tabulation of the final voting results.

That concludes the business items for consideration at today's meeting. Thank you for your participation. The meeting is now adjourned.

Unknown Attendee

The meeting has concluded. Thank you for joining. You may now disconnect.

Finanzdaten von BeyondSpring Inc.

Gewinn- und VerlustrechnungGuV Bilanz Cashflow

Quartal TTM Jährlich

Mär '26		+/- %
Umsatz	- -	- 100 %
- Direkte Kosten	- -	- -
Bruttoertrag	- -	- -
- Vertriebs- und Verwaltungskosten	3,98 3,98	39 % 39 % -
- Forschungs- und Entwicklungskosten	4,59 4,59	64 % 64 % -
EBITDA	-8,54 -8,54	4 % 4 % -
- Abschreibungen	0,03 0,03	92 % 92 % -
EBIT (Operatives Ergebnis) EBIT	-8,57 -8,57	8 % 8 % -
Nettogewinn	-7,64 -7,64	123 % 123 % -

Angaben in Millionen USD.

Auf Wunsch erhältst Du jeden Morgen pünktlich zum Frühstück eine E-Mail, die alle für Dich relevanten Aktien-News enthält.

News kostenlos abonnieren

BeyondSpring Inc. Aktie News

Neutral

GlobeNewsWire

●

vor 26 Tagen

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

FLORHAM PARK, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need, today announced a leadership transition designed to deliver focused, disciplined execution on BeyondSpring's most important near-term objective: completing DUBLIN...

Neutral

GlobeNewsWire

●

vor 28 Tagen

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced updated efficacy and safety data from the investigator-initiated Phase 2 303 Study evaluating pembrolizumab plus Plinabulin and docetaxel in patients ...

Neutral

GlobeNewsWire

●

vor etwa einem Monat

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada,...

Weitere BeyondSpring Inc. News

Firmenprofil

BeyondSpring, Inc. ist ein Unternehmen im klinischen Stadium, das sich mit der Entwicklung von Krebstherapien beschäftigt. Es konzentriert sich auf nicht-kleinzelligen Lungenkrebs, Neutropenie-Prävention sowie Plinabulin und Nivolumab. Das Unternehmen wurde 2013 von Lan Huang und Lin Qing Jia gegründet und hat seinen Hauptsitz in New York, NY.

Hauptsitz	Cayman-Inseln
CEO	Dr. Huang
Mitarbeiter	44
Gegründet	2010
Webseite	www.beyondspringpharma.com

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Jetzt starten